Systemic role for vitamin d in the treatment of psoriasis and metabolic syndrome
Lisa Wenyang Fu, Ronald Vender, Lisa Wenyang Fu, Ronald Vender
Abstract
The novel discovery of the systemic role of vitamin D in the modulation of the immune system especially the Type 1 helper T cell (Th1) pathway reveals its potential for treating Th1 inflammatory diseases. Psoriasis has been recently established to be a systemic disease centered on inflammation and involvement of cytokines of the Th1 pathway. There is an increased prevalence of metabolic syndrome in patients with psoriasis. Metabolic syndrome also involves a proinflammatory state. This paper proposes the idea of the potential use of oral vitamin D to treat psoriasis and metabolic syndrome concurrently. We propose there is merit in more clinical trials investigating the use of vitamin D to treat both psoriasis and metabolic syndrome through its anti-inflammatory effects. On application to psoriasis management and prognosis, the goal is to decrease the risk for cardiovascular disease and decrease disease morbidity and mortality.
References
- Holick MF. Medical progress: vitamin D deficiency. The New England Journal of Medicine. 2007;357(3):266–281.
- Ikeda U, Wakita D, Ohkuri T, et al. 1α,25-dihydroxyvitamin D3 and all-trans retinoic acid synergistically inhibit the differentiation and expansion of Th17 cells. Immunology Letters. 2010;134(1):7–16.
- Cantorna MT, Zhu Y, Froicu M, Wittke A. Vitamin D status, 1,25-dihydroxyvitamin D3, and the immune system. American Journal of Clinical Nutritio. 2004;80(supplement):1717S–1720S.
- Schön MP, Boehncke WH. Psoriasis. The New England Journal of Medicine. 2005;352(18):1899–1912.
- Langley RGB, Krueger GG, Griffiths CEM. Psoriasis: epidemiology, clinical features, and quality of life. Annals of the Rheumatic Diseases. 2005;64(supplement 2):ii18–ii23.
- Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet. 2007;370(9583):263–271.
- Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005;365(9468):1415–1428.
- Cameron AJ, Shaw JE, Zimmet PZ. The metabolic syndrome: prevalence in worldwide populations. Endocrinology and Metabolism Clinics of North America. 2004;33(2):351–375.
- Gisondi P, Tessari G, Conti A, et al. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. British Journal of Dermatology. 2007;157(1):68–73.
- Peternel S, Kaštelan M. Immunopathogenesis of psoriasis: focus on natural killer T cells. Journal of the European Academy of Dermatology and Venereology. 2009;23(10):1123–1127.
- Moller DE, Kaufman KD. Metabolic syndrome: a clinical and molecular perspective. Annual Review of Medicine. 2005;56:45–62.
- Gottlieb AB, Chao C, Dann F. Psoriasis comorbidities. Journal of Dermatological Treatment. 2008;19(1):5–21.
- Sommer DM, Jenisch S, Suchan M, Christophers E, Weichenthal M. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Archives of Dermatological Research. 2006;298(7):321–328.
- Azfar RS, Gelfand JM. Psoriasis and metabolic disease: epidemiology and pathophysiology. Current Opinion in Rheumatology. 2008;20(4):416–422.
- Naldi L, Addis A, Chimenti S, et al. Impact of body mass index and obesity on clinical response to systemic treatment for psoriasis: evidence from the psocare project. Dermatology. 2008;217(4):365–373.
- Hossler EW, Maroon MS, Mowad CM. Gastric bypass surgery improves psoriasis. Journal of the American Academy of Dermatology. In press.
- Libby P. Inflammation in atherosclerosis. Nature. 2002;420(6917):868–874.
- Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. Journal of the American Medical Association. 2006;296(14):1735–1741.
- Gelfand JM, Troxel AB, Lewis JD, et al. The risk of mortality in patients with psoriasis: results from a population-based study. Archives of Dermatology. 2007;143(12):1493–1499.
- Mehta NN, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the general practice research database. European Heart Journal. 2010;31(8):1000–1006.
- Mottillo S, Filion KB, Genest J, et al. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. Journal of the American College of Cardiology. 2010;56(14):1113–1132.
- Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001;24(4):683–689.
- Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. Journal of the American Medical Association. 2002;288(21):2709–2716.
- Abramovits W. Calcitriol 3 microg/g ointment: an effective and safe addition to the armamentarium in topical psoriasis therapy. Journal of Drugs in Dermatology. 2009;8(supplement 8):s17–s22.
- Van De Kerkhof PCM. The topical treatment of psoriasis. Clinical and Experimental Dermatology. 2005;30(2):205–208.
- Tanghetti EA. The role of topical vitamin D modulators in psoriasis therapy. Journal of Drugs in Dermatology. 2009;8(supplement 8):s4–s8.
- Lehmann B. Role of the vitamin D pathway in healthy and diseased skin—facts, contradictions and hypotheses. Experimental Dermatology. 2009;18(2):97–108.
- Perez A, Raab R, Chen TC, Turner A, Holick MF. Safety and efficacy of oral calcitriol (1,25-dihydroxyvitamin D) for the treatment of psoriasis. British Journal of Dermatology. 1996;134(6):1070–1078.
- Werner de Castro GR, Neves FS, Pereira IA, Fialho SC, Ribeiro G, Zimmermann AF. Resolution of adalimumab-induced psoriasis after vitamin D deficiency treatment. Rheumatology International. In press.
- Botella-Carretero JI, Alvarez-Blasco F, Villafruela JJ, Balsa JA, Vázquez C, Escobar-Morreale HF. Vitamin D deficiency is associated with the metabolic syndrome in morbid obesity. Clinical Nutrition. 2007;26(5):573–580.
- Matilainen JM, Husso T, Toropainen S, et al. Primary effect of 1α,25(OH)2D3 on IL-10 expression in monocytes is short-term down-regulation. Biochimica Biophysica Acta. 2010;1803(11):1276–1286.
- Tzotzas T, Papadopoulou FG, Tziomalos K, et al. Rising serum 25-hydroxy-vitamin D levels after weight loss in obese women correlate with improvement in insulin resistance. Journal of Clinical Endocrinology and Metabolism. 2010;95(9):4251–4257.
- Chiu KC, Chu A, Go VLW, Saad MF. Hypovitaminosis D is associated with insulin resistance and β cell dysfunction. American Journal of Clinical Nutrition. 2004;79(5):820–825.
- Alvarez JA, Ashraf A. Role of vitamin d in insulin secretion and insulin sensitivity for glucose homeostasis. International Journal of Endocrinology. 2010;2010 Article ID 351385.
- Maki KC, Rubin MR, Wong LG, et al. Serum 25-hydroxyvitamin D is independently associated with high-density lipoprotein cholesterol and the metabolic syndrome in men and women. Journal of Clinical Lipidology. 2009;3(4):289–296.
- Pittas AG, Lau J, Hu FB, Dawson-Hughes B. Review: the role of vitamin D and calcium in type 2 diabetes. A systematic review and meta-analysis. Journal of Clinical Endocrinology and Metabolism. 2007;92(6):2017–2029.
- McConnell JP, Foley KF, Vargas GM. Hypovitaminosis D: a new risk marker for cardiovascular disease. Clinical Laboratory Science. 2009;22(4):240–246.
- Wang TJ, Pencina MJ, Booth SL, et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation. 2008;117(4):503–511.
Source: PubMed